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Abstract
Introduction The sodium iodide symporter (NIS) directs the
uptake and concentration of iodide in thyroid cells. This in turn
allows radioiodine imaging and therapy for thyroid cancer. To
extend the use of NIS-mediated radioiodine therapy to other
types of cancer, we successfully transferred and expressed the
sodium-iodide symporter (NIS) gene in prostate, colon, and
breast cancer cells both in vivo and  in vitro by using non-
replicating adenoviral vectors.
Methods To improve virotherapy efficiency, we developed a
conditionally replicating adenovirus (CRAd) in which the
transcriptional cassette RSV promoter-human NIScDNA-bGH
polyA was also inserted at the E3 region. The E1a gene is driven
by the tumor-specific promoter MUC-1 in the CRAd
Ad5AMUCH_RSV-NIS.
Results In vitro infection of the MUC-1-positive breast cell line
T47D resulted in virus replication, cytolysis, and release of
infective viral particles. Conversely, the MUC-1-negative breast
cancer cell line MDA-MB-231 was refractory to the viral
cytopathic effect and did not support viral replication. The data
indicate that Ad5AMUCH_RSV-NIS activity is stringently
restricted to MUC-1-positive cancer cells. Radioiodine uptake
was readily measurable in T47 cells infected with
Ad5AMUCH_RSV-NIS 24 hours after infection, thus confirming
NIS expression before viral-induced cell death.
Conclusions This construct may allow multimodal therapy,
combining virotherapy with radioiodine therapy to be developed
as a novel treatment for breast and other MUC1-overexpressing
cancers.
Introduction
The American Cancer Society's most recent estimates for
breast cancer in the United States for 2009 are as follows:
192,370 new cases of invasive breast cancer and 40,170
deaths of breast cancer. Breast cancer is the most common
cancer among women in the United States, other than skin
cancer. It is the second leading cause of cancer death in
women, after lung cancer [1]. Breast cancer is particularly dif-
ficult to treat when it metastasizes and becomes resistant to
antiestrogen therapies [2].
The sodium iodide symporter (NIS) is a transmembrane glyco-
protein that mediates uptake of iodide into cells, especially thy-
roid follicular cells [3,4]. The presence of NIS on the
basolateral membrane of thyroid cells has been exploited for
many years for diagnostic imaging purposes, as well as for
ablative therapy of differentiated thyroid cancer by using radi-
Ad5: adenovirus serotype 5; bGH: bovine growth hormone; BIS-TRIS: bis(2-hydroxyethyl)iminotris(hydroxymethyl)methane; CAR: coxsackievirus ade-
novirus receptor; CIP: calf intestine phosphatase; CPE: cytopathic effect; CRAd: conditionally replicating adenovirus; EDTA: ethylenediamine-
tetraacetic acid; HBSS: Hanks' buffered salt solution; LTR: long terminal repeat; MOI: multiplicity of infection; MTS: [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; MUC-1: mucin-1; NIS: sodium iodide symporter; PBS: phosphate-buffered saline; PCR: 
polymerase chain reaction; polyA: polyadenylation signal; RSV: Rous sarcoma virus; RT: room temperature; TBS-T: Tris-buffered saline Tween-20.Breast Cancer Research    Vol 11 No 4    Trujillo et al.
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oactive iodide (131I). This noninvasive therapy has proven to be
a safe and effective treatment for thyroid cancer, even in
advanced, metastatic disease [5,6]. To extend the use of NIS-
mediated radioiodine therapy to other types of cancer, we suc-
cessfully transferred and expressed the sodium-iodide sym-
porter (NIS) gene in prostate, colon, and breast cancer cells,
both in vivo and in vitro, by using adenoviral vectors. Our expe-
rience with adenovirus-mediated NIS transfer and radioiodine
therapy was confirmed in a large animal model and has culmi-
nated in the opening of a phase I trial for prostate cancer that
is currently in progress [7-12].
MUC-1 is a highly glycosylated transmembrane mucin.
Although MUC-1 is expressed at very low levels in normal tis-
sues; it is overexpressed by most carcinomas, including breast
cancers [13]. Enhanced expression of MUC-1 is regulated
mostly at the level of transcription [14]. The pronounced differ-
ential expression of MUC-1 in tumor versus normal tissues has
been used in experimental developments of antitumor thera-
pies, including MUC-1 vaccines and MUC-1 promoter-
restricted antitumor-specific viruses [15-17].
All gene-therapy approaches depend on the ability to deliver
therapeutic genes to target cells. However, the limited ability
to transduce tumors efficiently with effective levels of thera-
peutic transgenes has been identified as the fundamental bar-
rier to effective cancer gene therapy [18,19]. To address this
issue, conditionally replicating viruses, including adenovirus,
have been constructed, and their efficacy, evaluated [20-22].
Our approach to the current problems associated with viro-
therapy/gene therapy has been the development of tumor-spe-
cific, conditionally replicating adenoviral vectors that also
harbor the NIS gene. We report here the development of a
conditionally replicating adenovirus (CRAd) in which the E1a
gene is driven by the tumor-specific promoter MUC-1. In addi-
tion, the transcriptional cassette RSV promoter-hNIScDNA-
bGH polyA was inserted at the E3 region. Our results suggest
that this CRAd may represent a novel approach to breast can-
cer gene therapy.
Materials and methods
Cell culture
The breast cancer cell lines T47D and MDA-MB-231 were
used to examine CRAd Ad5AMUCH_RSV-NIS specificity.
Adenovirus infection was performed for 4 hours in serum-free
media. Cells were then washed once with PBS and replen-
ished with fresh culture media. The human embryonic kidney
cell line stably expressing E1A (HEK 293) was obtained from
Cell Biolabs, Inc., San Diego, CA. Cells were cultured as
described [8,23].
CRAd construct and cell lines
The E1A gene flanked by a 5' blunt end, and an EcoRI 3' end
was isolated from plasmid pCD512_F2 (a gift of Dr. Richard
Vile, Mayo Clinic) and cloned into the Promega vector pGL3-
Basic to yield pGL3E1. The MUC-1 promoter (a gift of Dr.
Sandra Gendler, Mayo Clinic Arizona) was PCR amplified by
using the forward primer AAAAAGGTACCGGACCCTAGGGT-
TCATCGGAG and the reverse primer AAAAAAGATCTGAT-
TCAGGCAGGCGCTGGCTGC from the plasmid pcDNA3
[8]. The resulting PCR fragment 0.726 Kb spanning nt2188 to
nt2914 was cloned into pGL3E1 to yield pGL3MUCH. The
MUC-1 promoter-E1A-SV40 PolyA fragment was excised
from pGL3MUCH by digestion with EcoRI/KpnI and cloned
into the shuttle vector pVQA-PB-NIS [23] restricted by KpnI/
EcoRI and dephosphorylated with CIP to generated pVQA-
MUCH. The human NIS cDNA under Rous Sarcoma Virus
LTR promoter control was subcloned into an Ad5 genomic
vector containing an E3-deleted version (ViraQuest, North Lib-
erty, IA, USA). The pVQAMUCH shuttle vector and the NIS-
containing Ad5 genomic plasmid were recombined to yield the
CRAd Ad5AMUCH_RSV-NIS. Plaques were grown, purified,
and characterized by ViraQuest as previously described [23].
The replication-incompetent Muc promoter-driven luciferase
expression vector, AdEasyMucLuc, was constructed through
homologous recombination in Escherichia coli by using the
AdEasy system [24]. This vector has the transgene cassette in
the E1 deleted region of an adenoviral vector backbone. The
vector was constructed as follows: the MUC_1 promoter was
derived from a plasmid pGL3MUCH and cloned into plasmid
pShuttleGL3B [25] by using KpnI and HindIII sites. The result-
ant plasmid, pShuttleMuc_GL3B, was linearized with PmeI
digestion and subsequently co-transformed into E. coli
BJ5183 with the pAdEasy-1 Ad backbone plasmid. After
selection of recombinants in these bacteria, the recombinant
DNA was linearized with PacI digestion and transfected into
293 cells to generate AdEasyMucLuc. The virus was propa-
gated in 293 cells, dialyzed in phosphate-buffered saline
(PBS) with 10% glycerol, and stored at -80°C. Titering was
performed with a plaque-forming assay by using 911 cells and
optical density-based measurement.
MUC-1 flow cytometry
The 106 exponentially growing cells were washed with PBS
containing 1 mmol/L EDTA and resuspended in PBS. Cells
were incubated with 20 μg/ml mouse anti-human MUC-1 anti-
body (Cell Signaling Technology Inc. Beverly, MA, USA) 30
min at RT. Controls cells were processed equally, except that
they were incubated with 20 μg/ml mouse anti-human (IgG1)
TNP anti-isotype antibody control (BD Biosciences Pharmin-
gen, SanDiego, CA, USA). Cells were then washed in PBS
and incubated with FITC-conjugated goat anti-mouse IgG
secondary antibody (BD Biosciences Pharmingen) (1:100) for
30 min at RT. Cells were then washed, resuspended in PBS,
and immediately analyzed with a Becton Dickinson FACScan
by using CELLQuest software.Available online http://breast-cancer-research.com/content/11/4/R53
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Protein isolation and Western blots
For all Western blots, the protein concentration was measured
in triplicate, and two gels were run. The first was developed
with silver staining by using the PlusOne Silver Staining Kit,
Protein (GE Healthcare Bio-Sciences, Uppsala, Sweden)
according to the manufacturer's instruction and quantitated by
using the ImageJ software [26]. This gel served as loading
control (not shown). The second gel was blotted onto nitrocel-
lulose and Western blotted. E1a and hexon extracts were pre-
pared from 4 × 106 cells grown on 100-mm tissue-culture
plates and infected at MOI 20. At noted time points, cells were
rinsed twice in HBSS before lysis in 1 ml of the complete lysis-
M reagent with supplied protease inhibitors (Roche Applied
Science, Indianapolis, IN, USA) on ice with shaking for 5 min-
utes and then quantified by using the DC protein assay (Bio-
Rad Hercules, CA, USA). Membrane proteins extracts were
prepared for NIS and CAR Western blotting as described
[27]. Lysate aliquots, 1 μg of protein, were electrophoresed by
using I a X cell II Blot Module (Invitrogen, Carlsbad, CA, USA)
on 10% BIS-TRIS polyacrylamide gels under reducing condi-
tions at 200 V for 1 hour. Proteins were then blotted to nitro-
cellulose membranes at 25 V for 1 hour and processed with
the ECL advanced Western blot detection kit (GE Healthcare,
Uppsala, Sweden) according to the manufacturer's instruc-
tions. E1A primary antibody (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) was diluted 1:20,000, and the anti-Ad5 hexon
IgG (Santa Cruz Biotechnology), 1:100,000. Anti-CAR analy-
ses were performed by running 5 μg of membrane protein or
1 μg of cell extract on a 10% Bis-Tris polyacrylamide gels
under nonreducing conditions. Blocking steps were per-
formed as described earlier. Blots were incubated with primary
mouse Anti-CAR, clone RmcB (Upstate Cell Signaling Solu-
tions Inc., Danvers, MA, USA). The antibody was diluted
1:10,000 in TBS-T with 0.1% blocking reagent for 90 minutes.
NIS Western blots were performed as previously described
[27].
Cytopathic effect assays
The 1 × 106 cells were infected at MOI 1. At noted time points,
the cells were photographed under a light microscope at
100× magnification.
MTS assay
The 5 × 104 cells were seeded in 96-well tissue-culture plates
and incubated at 37°C, 5% CO2 in triplicate. Twenty-four
hours after plating, the cells were infected at the indicated
MOI. The virus-containing medium was exchanged with fresh
medium, and at each time point, 50 μl of CellTiter 96 Aqueous
One Solution Cell Proliferation Assay (Promega Corporation,
Madison, WI, USA) was applied and then incubated at 37°C,
5% CO2 for 2 hours. Absorbance was then read at 490 nm by
using a plate spectrophotometer.
Replication assay of the CRAd vector
The 4 × 106 cells were plated in 150-cm2 culture flasks and
infected at MOI 1 and MOI 0.1. Seventy-two hours after infec-
tion, virus was harvested from media and cells separately and
purified by using the ViraBind Adenovirus Purification Kit (Cell
Biolabs, San Diego, CA, USA). Virus titers were quantified by
plaque assay on HEK 293 cells.
125I uptake
Uptake of 125I by virus-infected cells was measured as
described [10,28]. In brief, 1 × 106 cells/well were plated on
36-well tissue-culture plates and infected at MOI 0, 0.5, 5, 10,
20, and 50. At indicated time points, iodide-uptake measure-
ment was performed in triplicate in HBSS supplemented with
10 mmol/L HEPES, pH 7.3, 10 μmol/L NaI, and 1 × 105 cpm
of 125I. Control wells were incubated in the same buffer plus
10 μmol/L KClO4. Plates were gently mixed and incubated at
37°C, 5% CO2, for 45 minutes. After incubation, buffers were
aspirated and the cells gently washed once with 4°C 10
mmol/L HEPES, pH 7.3 buffer. Cells were lysed in 1 ml 1 N
NaOH with shaking for 20 minutes at RT, and lysates were
assayed for 125I on a gamma counter.
Noninvasive imaging of xenografted tumors
All experimental protocols were reviewed and approved by the
Mayo Clinic Institutional Animal Care and Use Committee
(IACUC). Xenografts derived from the T47D cell line were
established on each flank of 6-week-old athymic nude
Foxn1nu mice (Harlan, Madison, WI, USA) by subcutaneous
injection of 4 × 106 cells resuspended in 0.125 μl media and
0.125 μl of BD Matrigel basement membrane matrix (BD Bio-
sciences, Bedford, MA). Mice were maintained on a low-iodine
diet and T4 supplementation (5 mg/L) in their drinking water
throughout the duration of the experimentation to maximize
radioisotope uptake in the tumor and minimize uptake by the
thyroid [8-10]. The mice were examined daily for tumor growth.
Tumor volume was measured with calipers twice weekly and
calculated by the formula:
When tumors reached 100 mm3, mice received one intratu-
moral (IT) injection of 1011 vp of the AdAMUCH_RSV-NIS
CRAd on the left flank; the right flank served as control. Two
days later, an intraperitoneal dose of 0.5 mCi of 123I sodium
iodide was given, and 1 hour later, radioiodine imaging was
performed by using a γ-camera equipped with a low-energy
high-resolution collimator (VG System; GE Healthcare, Mil-
waukee, WI). Regions of uptake were quantified and
expressed as a fraction of the total amount of the applied radi-
oiodine.
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Results
Virus construction
The conditionally replicating adenoviruses (CRAd)
Ad5AMUCH_RSV-NIS harbors the transcriptional cassette
RSV promoter-human NIScDNA-bGH polyA inserted at the
E3 region. In this CRAd, the E1a gene is driven by a 0.726-Kb
version of the tumor-specific MUC-1 promoter spanning
nt2188 to nt2914 [17] (Figure 1).
MUC-1 and CAR expression
Two breast cancer cell lines, T47D and MDA-MB-231, were
characterized for their expression of MUC-1. No difference in
the flow-cytometry histogram was found between the isotype
control and the MUC-1 antibody in MDA-MB-231, confirming
that this cell line is MUC-1- (data not shown). We then zeroed
the FACScan by using this cell line and analyzed the T47D
under this new setting. This analysis revealed that T47D is
MUC-1 positive, whereas MDA-MB-231 is MUC-1 negative
(Figure 2a). Moreover, when these two cell lines were infected
with the nonreplicating virus AdEasyGL3B-Muc, in which the
Luc gene is driven by the MUC-1 promoter, only the T47D cell
line supported MUC-1-driven Luc activity, whereas MDA-MB-
231 was completely negative (Figure 2b). To exclude the pos-
sibility that inability to support viral replication was due to lack
of CAR-receptor expression, CAR-receptor expression was
assayed with Western blot of membrane extracts prepared
from the two cell lines. To control for protein loading, identical
amounts of protein were loaded on a second gel that was sil-
ver stained for protein assessment (not shown). The insert in
Figure 2a supports the notion that both cell lines readily
express the CAR receptor at the cell plasma membrane. We
conclude that T47D is MUC-I positive, whereas MDA-MB-231
is MUC-1 negative, and that both cell lines express CAR and
thus are capable of being infected by wild-type capsid Ad5.
Conditional replication, oncolysis, and spread of 
Ad5AMUCH_RSV-NIS
We examined the specificity of Ad5AMUCH_RSV-NIS repli-
cation by using several methods. First, we examined the spe-
cificity of viral proteins expression. MUC-1-driven E1A and
Hexon expression were examined with Western blotting.
T47D and MDA-MB-2321 cells were infected with
Ad5AMUCH_RSV-NIS at MOI 20. Figure 3 shows two major
differences between the permissive T47D cell line and the
nonpermissive MDA-MB-231. Only cells infected with
Ad5AMUCH_RSV-NIS expressed viral proteins. Most impor-
tant, a marked difference was noted in the quality and quanti-
ties of viral protein expressed in the permissive cell compared
with the nonpermissive cell line (Figure 3a). We also examined
hexon expression, a product of late protein synthesis and a
very good indicator of viral assembly [29]. Here again, the
amount of hexon protein produced 48 hours after infection in
the permissive cell line T47D outperformed that produced in
nonpermissive cell lines MDA-MB-231 (Figure 3b).
Cells infected with Ad5PB_RSV-NIS at MOI 1 were monitored
for viral-induced cytopathic effect (CPE) by light microscopy.
Four days after infection, the morphology of the MDA-MB-231
cells was unchanged; however, clear signs of CPE in T47D
are detected under the same conditions of infection (Figure 4).
To address the issue of virus specific cell killing, the permis-
sive cell line T47D was infected with the Ad5AMUCH_RSV-
NIS CRAd at increasing MOIs and then assayed daily by MTS.
The results were compared with those obtained with the non-
permissive cell line MDA-MB-231. The T47D cells showed a
reduced viability that was both time and dose dependent (Fig-
ure 5a). Conversely, MDA-MB-231 viability was completely
refractory to virus-mediated cell killing (Figure 5b).
Virus-progeny production after infection with the
Ad5AMUCH_RSV-NIS CRAd was measured in T47D, and
MDA-MB-231 cells 3 days after infection at MOI 1 or 0.1 by
burst assay (Figure 6). To distinguish between released and
intracellular virus, media and cell were separated, and virus
was purified separately from each. The amount of virus pro-
duced by the T47D cells was 6 orders of magnitude greater
than the amount produced by the MDA-MB-231 cells.
Taken together, these data demonstrate that replication of the
Ad5AMUCH_RSV-NIS virus is stringently restricted to MUC-
Figure 1
Structure of the Ad5AMUCH_RSV-NIS CRAd Structure of the Ad5AMUCH_RSV-NIS CRAd. The E1A gene is driven by the tumor-specific mucin-1 (MUC-1) promoter. The Rous sarcoma virus 
(RSV) promoter drives expression of the sodium iodide symporter (NIS) gene inserted at the E3 region.A va ila b le  o n lin e http://breast-cancer-research.com/content/11/4/R53
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1-positive breast cancer cells, defining this virus as a condi-
tionally-replicating adenovirus or CRAd.
NIS expression and radioiodine uptake
Expression of the NIS protein was examined with Western
blotting by using a mouse monoclonal anti-human NIS anti-
body [30]. Figure 7a shows that T47D and MDA-MB-231 cells
transfected with the Ad5PB_RSV-NIS CRAd expressed NIS,
which was detected as a broad band spanning from 130 Kd
to 110 kDa. Visualization of the NIS band as a smear is
expected; it reflects differences in NIS glycosylation [30,31].
Expression of the NIS gene in the nonpermissive cell line
MDA-MB-231 is supported by the RSV ubiquitous promoter
and shows that this cell line is susceptible to Ad5 infection.
Having shown that infected cells are capable of expressing
membrane-bound NIS, we next investigated whether the pro-
tein was functional. Dose-response and kinetic curves of
iodine uptake were constructed. Infection of T47D cells with
Ad5AMUCH_RSV-NIS at MOI 20 showed maximal uptake at
24 hours after infection, followed by a twofold decrease in 125I
uptake at later time points (Figure 7b). Radioiodine uptake was
inhibited by KClO4, a well-known inhibitor of NIS activity [3].
We infer from this result that an optimal time window exists for
NIS-mediated radioiodine uptake in the permissive cells, after
Figure 2
Mucin-1 (MUC-1) and coxsackievirus adenovirus receptor (CAR) expression Mucin-1 (MUC-1) and coxsackievirus adenovirus receptor (CAR) expression. (a) Relative membrane MUC-1 expression in T47D (black line) and 
MDA-MB-231 cells (gray line) was measured with flow cytometry. Insert: Western blot with an anti-CAR receptor antibody of membrane proteins 
extracted from T47D and MDA-MB-231 cells. (b) MUC-1 promoter expression was monitored in T47D and MDA-MB-231 by measuring MUC-1-
driven expression of luciferase activity after transduction with the nonreplicating virus AdEasyGL3B-Muc.
Figure 3
Viral proteins expression Viral proteins expression. Expression of E1A (a) was assayed in T47D and MDA-MB-23) cells. Cells were infected with Ad5AMUCH_RSV-NIS at 
multiplicity of infection (MOI) 20, and extracts were prepared at 24 hours after infection and compared with extracts from noninfected cells. (b) 
Hexon expression was assayed in MDA-MB-231 and T47D 48 hours after infection and compared with uninfected cells. HEK 293 cells infected with 
Ad5AMUCH_RSV-NIS were used as control.Breast Cancer Research    Vol 11 No 4    Trujillo et al.
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which, uptake, and as a consequence, NIS expression
declines. This might be due to virus replication and induction
of CPE. Twenty-four hours after infection, a radioiodine uptake
dose-response to increasing MOI concentrations was built.
Figure 7c shows that radioiodine uptake was linear over the
range of MOI used in the experiment.
Having shown in cell culture that Ad5AMUCH_RSV-NIS can
infect, multiply, and direct NIS expression in permissive cells,
we wished to confirm that viral infection and NIS expression
also take place in vivo. Figure 8 reveals strong 123I uptake by
the T47D tumor that has been injected with the Ad5PB_RSV-
NIS CRAd 48 hours after infection. Quantitation of the image
yielded an uptake in infected tumors of more than 30% of the
injected dose at 1 hour. The stomach and thyroid also were
imaged because of native NIS expression, and the bladder,
because of tracer excretion [9].
Taken together our results demonstrate that
Ad5AMUCH_RSV-NIS directs NIS expression in permissive
cells before the onset of cell lysis.
Discussion
Although a number of gene-therapy approaches have been
developed for many cancers, clinical trials completed to date
have fallen short of expectations [32-36], largely due to limited
tumor transduction, and this limitation has been defined as the
most important fundamental barrier to effective cancer gene
therapy [37]. Our approach to addressing the problem of low
tumor transduction is to allow vector replication by using con-
ditionally replicating adenovirus.
We used a transcriptional-regulation method placing the E1A
gene under control of the tumor-specific promoter MUC-1.
The rationale for this choice is based on the observation that
transcriptional-dependent regulation seems to be the most
efficient strategy for CRAd development [38]. In addition, we
inserted the NIS gene under control of the powerful but non-
specific RSV promoter. We used a truncated version of the
MUC-1 promoter that was previously shown to be specifically
active in MUC-1-positive breast cancer cell lines [17]. The
rationale and utility for use of this promoter is that more than
90% of breast tumors overexpress the MUC-1 gene [13]. By
this method, viral replication, and consequently extended NIS
Figure 4
Cytopathic effect Cytopathic effect. Ad5PB_RSV-NIS-induced cytopathic effect was 
assessed with light microscopy 4 days after infection in T47D and 
MDA-MB-231 cells.
Figure 5
Cell-proliferation assay Cell-proliferation assay. (a) T47D and (b) MDA-MB-231. Cells were infected with Ad5PB_RSV-NIS, and cell viability was monitored daily by using 
MTS assay.Available online http://breast-cancer-research.com/content/11/4/R53
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expression, will target a wide spectrum of MUC-1-positive
breast tumors.
In the present study, we confirmed that this MUC-1 promoter
version restricts viral protein synthesis, cytopathic effect, cell
lysis, and infectious viral progeny production to MUC-1-posi-
tive breast cancer cells. Moreover, the bulk of viral progeny
produced by the MUC-1-positive breast cancer cell line T47D
was found in the media, indicating that viral infection of T47D
cells with the Ad5AMUCH_RSV-NIS CRAd resulted in cell
lysis and subsequent release of infectious viral particles. We
hypothesize that the release of infectious viral particles should
allow wide viral spread within tumors. Virus specificity was
demonstrated by using the MUC-1-negative breast cancer cell
line MDA-MB-231. The MDA-MB-231 cell line expresses cell-
surface CAR receptor because we visualized CAR expression
in membrane-bound electrophoresed proteins. It supports lim-
ited E1A and hexon expression and supports NIS expression.
All these data confirm that MDA-MB-231 is infected by the
Ad5AMUCH_RSV-NIS, yet it is resistant to CRAd-induced
Figure 6
Cell-specific replication of Ad5AMUCH_RSV-NIS Cell-specific replication of Ad5AMUCH_RSV-NIS. T47D and MDA-
MB-231 cells were infected with Ad5AMUCH_RSV-NIS at multiplicity 
of infection (MOI) 1 or MOI 0.1. Viral progeny were isolated from media 
and cells and quantitated with plaque assay on 293 cells.
Figure 7
Analysis of sodium iodide symporter (NIS) expression Analysis of sodium iodide symporter (NIS) expression. (a) NIS expression assayed with Western blotting in Ad5AMUCH_RSV-NIS-infected cells. 
Membrane proteins were prepared 24 hours after infection. (b) Radioiodine uptake dose-response. T47D cells were infected at the indicated multi-
plicity of infection (MOI). Radioiodine uptake was measured 24 hours after infection. (c) Kinetics of NIS-mediated radioiodine uptake. T47D cells 
were infected at MOI 20 with the Ad5AMUCH_RSV-NIS conditionally replicating adenovirus (CRAd), and 125I uptake was measured daily.Breast Cancer Research    Vol 11 No 4    Trujillo et al.
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oncolysis or viral replication or both. These data demonstrate
that the Ad5AMUCH_RSV-NIS CRAd is stringently depend-
ent on MUC-1 overexpression and should not replicate within
normal tissue, where MUC1 expression is minimal.
The NIS protein must be properly targeted to the cell plasma
membrane to be functional [39]. Our results also showed that
the Ad5AMUC_RSV-NIS CRAd directs correct NIS expres-
sion and thus radioiodine uptake in vitro and in vivo. Under the
control of the RSV promoter, the NIS protein was correctly tar-
geted to the cell plasmamembrane, thereby promoting high
levels of iodine uptake in T47D cells. Our results also show
that in MUC-1-negative CAR-positive breast cancer tumors,
the NIS gene also can be expressed, because it is under the
control of the ubiquitous RSV promoter. Here, the cell line
MDA-MB-231 showed very strong NIS protein expression by
Western blot, which translated to robust radioiodine uptake
(data not shown). Hence the Ad5AMUCH_RSV-NIS CRAd
could be used as a non-replicating NIS-expressing vector.
However, in this case, NIS gene expression was transient, thus
narrowing the window for radioiodine therapy and loss of the
combined radiovirotherapy.
A discrepancy is apparent in the kinetics of NIS expression
and luciferase expression that can be explained by several
influencing factors; First, the luciferase gene was cloned at the
E1 region of a nonreplicating adenovirus, under the control of
the MUC-1 promoter, whereas the NIS gene was cloned at
the E3 region of a replicating adenovirus under the RSV pro-
moter. Second, the stability of two very different mRNAs and
proteins cannot be assumed to be equal.
Finally, NIS is an integral membrane protein, whereas luci-
ferase remains cytoplasmic. Therefore, the pattern of expres-
sion of luciferase and NIS under these conditions is not
expected to overlap precisely.
NIS is already a therapeutic gene, in that its native expression
in thyroid cells is used for therapy for thyroid cancer and hyper-
thyroidism, where its efficacy is very high [6]. NIS expression
could represent an ideal therapeutic gene for breast cancer
therapy, because it allows a large bystander effect. Because
of the physics of 131I decay, which occurs primarily through
emission of a β particle that traverses up to 2 mm within the
tissue. Thus, not every cell must be transfected and express
NIS to be affected by radioiodine therapy. This is critical to the
effectiveness of any cancer gene-therapy strategy because of
the difficulty in achieving 100% transfection with the therapeu-
tic gene, even in the case of a replicating virus. Moreover, NIS
expression can be directly monitored and quantitated noninva-
sively. The uptake of radioiodine in tissues can be quantitated,
and both the distribution and the quantity of NIS expression
can be easily and safely monitored noninvasively.
The limited efficacy observed in clinical trials of cancer gene
therapies to date has suggested that combinatorial therapies
to treat cancer will likely be more effective and possibly
required for complete tumor eradication. The hypothesis
developed from this observation is that attacking tumor cells
through different mechanisms of action may prevent tumor
cells from developing resistance to the treatment combination
and may more effectively induce immunity against the tumor
[40]. We hypothesize that, because Ad5AMUC_RSV-NIS
CRAd harbors the NIS gene, it should improve the therapeutic
value of the CRAd by allowing multimodal therapy in a single
agent combining viral-mediated tumor lysis as well as radioio-
dine-mediated therapy.
Conclusions
In conclusion, the features of Ad5PB_RSV-NIS CRAd
address favorably the major hurdles identified in gene-therapy
clinical trials for anticancer treatments. Further evaluation,
including efficacy studies in animal models, is needed to deter-
mine the potential of this radio/virotherapy approach to affect
breast cancer treatment.
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